{
    "headline": "Merck Asks Fda Emergency Approval Antiviral Covid 19 Pill",
    "summary": "Pharmaceutical drugmaker Merck and its partner Ridgeback Biotherapeutics announced Monday that it has asked the Food and Drug Administration (FDA) for emergency approval of its\u00a0COVID-19 pill. The company says the pill, called molnupiravir, reduced the risk of hospitalization or death in patients with mild to moderate COVID-19 by about 50% in a late-stage clinical trial.\u00a0Researchers\u00a0at Emory University in Atlanta created the pill; using the pill\u00a0involves taking several twice a day for five days.\u00a0The Biden administrationcommitted $3.2 billion to the development of an antiviralin June.The news was covered prominently across the spectrum, especially by left- and center-rated outlets. Some reports from right-rated sources highlighted advocates who say the treatment's projected price \u2014 roughly $700 \u2014 is roughly 40 times the production cost.",
    "story": {
        "left": [
            "https://www.usatoday.com/story/news/health/2021/10/11/covid-vaccinations-molnupiravir-antiviral-pill-cases/6083682001/"
        ],
        "center": [
            "https://www.statnews.com/2021/10/04/what-we-know-and-dont-know-about-mercks-new-covid-19-pill/"
        ],
        "right": [
            "https://nypost.com/2021/10/11/merck-asks-fda-for-emergency-approval-of-its-antiviral-covid-19-pill/"
        ]
    }
}